The webinar will present a new, up-to-date and easy-to-use online platform that allows you to keep up to date with future drug approvals in Spain.
This tool, which compiles information since 2015, provides:
- Data on medicines at an early stage of the regulatory process.
- Historical data on already approved medicines
- Analyses based on historical data
- Knowledge of the pricing and reimbursement status in Spain of new medicines and new indications.
INMEDIATA is aimed at anybody interested in advance information on potential changes in the pharmaceutical market in order to formulate forward-looking strategies. To learn about the information collected in the new platform (INMEDIATA) and how to use it to generate trend analysis of future drug approvals as well as drugs undergoing P&R procedures in Spain.
Using INMEDIATA helps to:
Max Brosa holds a Master in Business Administration (MBA) from EADA and has been working in the field of economic evaluation and market access of health technologies since 1987, collaborating until today in different public and private organizations in Spain.
In 2005 he founded Oblikue Consulting (a Pharmalex company), which he has led since then, dedicated to market access consulting and research in the field of health economics, with a focus in the economic evaluation and pricing & reimbursement of new drugs. Oblikue Consulting is the leading market access consulting firm in Spain and has become the first organization (public or private) in number of publications on economic evaluation of health technologies in our country. It has participated in the development of the Guide and recommendations for the preparation and presentation of economic evaluations and budget impact analysis of medicines (GAEIP) of CatSalut and the Guide for the definition of criteria for the application of outcomes-based payment schemes in the pharmacotherapeutic field of the Catalan Health Service.
More than 12 years of experience in Market Access and health economics. Management of Price & Reimbursement projects of new drugs, cost of illness studies and healthcare cost and P&R databases.
Job Title, Company name
Praesent commodo cursus magna, vel scelerisque nisl consectetur et. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh.